Abstract library

47 results for "Boss".
#2169 Patient and Clinician Perspectives on Symptom Priorities Across the Spectrum of Neuroendocrine Tumors (NETs)
Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Research Prof Kimberly Webster
#1480 Systemic Treatment Sequences across Europe for Patients (pts) with Advanced Non-functional (NF) Well-Differentiated Pancreatic Neuroendocrine Tumours (WD pNETs)
Introduction: Different systemic therapies (ST) are available for pts with advanced WD pNETs; however, the best treatment modalities and optimal sequencing are currently unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: MD PhD Ana Custodio
#2032 Current Educational Strategies Used by Nurses Caring for NET Patients: Electronic Survey across 25 Countries
Introduction: The ENETS Nurse Group performed a short pilot survey in 2015 to locate nurses who take care of NET patients and to explore NET nurse education needs. The results of this survey were used to design a more detailed electronic survey.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Philippa Davies
#2035 Prevalence of Carcinoid Syndrome (CS) in the European Union (EU)
Introduction: Epidemiologic data on CS, which typically occurs in patients with advanced midgut or lung neuroendocrine tumors (NET), are scarce and appear to be heterogeneous across countries.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MSc Julie Mouchet
#2090 Financial Toxicity in Patients with Neuroendocrine Tumor Disease. A so far Underestimated "Side Effect" of Cancer in Germany?
Introduction: Cancer is not only associated with physical and psychological, but also financial burden. In contrast to other countries, the socio-economic impact of cancer for patients in Germany, with a third party paid health care system, is poorly understood.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof.Dr.Dr. Eva Caroline Winkler
#813 Comparison of Manual and Automatic Methods of Ki-67 Proliferation Index for Neuroendocrine Tumors: The Development and Validation of a Novel Digital Pathology Tool (Ki-67Counter)
Introduction: Ki-67 proliferation index is an increasingly important biomarker used to grade neuroendocrine tumors. Manual counting methods are laborious and subject to inter- and intra-observer variability. Digital counting methods hold promise for fast and reproducible indices, however, they are fraught with technical difficulties.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr. Lin Yang
Authors: Neltner J, Su H, Xing F, Rosser J, ...
#1490 Even Malignant Appendiceal Neuroendocrine Tumors Exhibit No Recurrent Chromosomal Alterations
Introduction: Neuroendocrine tumors (NETs) of the midgut are located in the ileum (iNET), caecum or appendix (aNET). Despite of the similar origin, NETs of the ileum and the appendix behave remarkably different. iNETs show high malignant potential, which manifests with early lymph node or liver metastases. Genetically, the loss of chromosome 18 (Ch18) in 60-74% of cases is the most frequent alteration in iNETs. aNETs are often incidental findings, rarely show metastases, and no chromosomal alterations are known.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Maike Nieser
Keywords: NET
#1672 PD-L1 Expression and Quantitative Assessment of Tumor-Infiltrating T Cell Subsets in Carcinoid Tumors and Large Cell Neuroendocrine Carcinomas of the Lung
Introduction: Little is known about the expression of PD-L1 an the immune infiltrate in neuroendocrine neoplasms of the lung.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Julien Hadoux
#1766 Videoconsultation During Follow-Up Care of Patients with a Neuroendocrine Tumor.
Introduction: Patients with a neuroendocrine tumor (NET) are increasingly treated in expert centers leading to longer travel times for medical consultations. Videoconsultation (VC) potentially allows remote guidance of patients.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: MD Grietje Bouma
#1884 Towards Optimal Personalized Diet and Vitamin Supplementation in NET Patients; A Feasibility Study
Introduction: Patients with a neuroendocrine tumor (NET) often have gastro-intestinal complaints due to somatostatin analogue (SSA), tumor mass, secretion of neuroendocrine amines or treatment. This can lead to impaired absorption of critical food components such as vitamins. Serotonin producing NET patients may also have low plasma tryptophan.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: drs Ld de Hosson